Plant-Based Active Pharmaceutical Ingredients (API) Market Report 2026

The plant-based active pharmaceutical ingredients (api) market size has grown strongly in recent years. It will grow from $32.08 billion in 2025 to $34.2 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to traditional medicine adoption, availability of medicinal plants, cost advantages over synthetic APIs, growth of herbal drug formulations, rising consumer preference for natural products.

The plant-based active pharmaceutical ingredients (api) market size is expected to see strong growth in the next few years. It will grow to $44.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to sustainability-driven API sourcing, expansion of plant-based drug pipelines, rising nutraceutical-pharma overlap, improved standardization techniques, global demand for green pharmaceuticals. Major trends in the forecast period include rising demand for natural and herbal APIs, expansion of phytochemical extraction technologies, growing use of plant APIs in chronic therapies, increasing regulatory acceptance of herbal APIs, shift toward sustainable API sourcing.

The rising consumer demand for natural and organic products is poised to fuel expansion in the plant-based active pharmaceutical ingredients (API) market. Natural and organic products are those derived from naturally sourced materials, undergo minimal processing, and exclude synthetic chemicals as well as genetically modified organisms (GMOs). This shift stems from heightened health awareness and worries about synthetic chemicals, with people increasingly mindful of the health risks posed by artificial ingredients. Plant-based APIs enable natural and organic products by delivering potent, chemical-free therapeutic effects that match consumer desires for pure, secure, and eco-friendly health options. For instance, in April 2025, the Organic Trade Association - a U.S.-based group for member businesses - reported that certified organic product sales in the U.S. surged 5.2% in 2024, outpacing the overall market's 2.5% growth by more than double, and reaching a record $71.6 billion. Thus, the increasing preference for natural and organic products is propelling the plant-based active pharmaceutical ingredients (API) market forward.

Major companies in the plant-based active pharmaceutical ingredients (API) market are prioritizing the creation of novel products like plant-based squalene, offering eco-friendly and ethical substitutes for conventional animal-sourced materials. Plant-based squalene serves as a sustainable, ethical replacement for squalene from sharks, derived from sources such as amaranth, olives, and sugarcane for applications in pharmaceuticals, cosmetics, and vaccines. For example, in October 2023, Evonik Industries AG - a specialty chemicals firm based in Germany - introduced PhytoSquene, the inaugural GMP-grade, plant-derived squalene from amaranth oil. This breakthrough delivers a green alternative to shark-sourced squalene, with superior purity, reliable batch consistency, and adherence to European Pharmacopoeia (Ph. Eur.) requirements. Squalene is vital in vaccine adjuvants, boosting immune reactions. Through this plant-based solution, PhytoSquene tackles biodiversity issues, cuts dependence on animal products, and aligns with cultural and religious needs.

In March 2024, Roquette Frères, a French supplier of pharmaceutical excipients, purchased IFF Pharma Solutions for an undisclosed sum. Through this acquisition, Roquette seeks to bolster its standing in the pharmaceutical excipients sector by broadening its product range and expertise in drug delivery. The deal speeds up expansion in the health and nutrition markets, solidifying Roquette’s status as a vital collaborator for pharma firms. IFF Pharma Solutions, a U.S.-based firm, specializes in plant-derived active pharmaceutical ingredients.

Major companies operating in the plant-based active pharmaceutical ingredients (api) market are Indena S.p.A., Centroflora Group, Alkaloids Corporation, Alchem International Pvt. Ltd., C2 Pharma, Brains Bioceutical Corp., Bright Green Corporation, Sichuan Xieli Pharmaceutical Co. Ltd., Roquette Frères, Koninklijke DSM N.V., Evonik Industries AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Seppic, PAI Pharma, SCL Lifesciences Ltd., AMGIS Lifescience Ltd., Organotechnie, HimPharm.

North America was the largest region in the plant-based active pharmaceutical ingredients (API) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plant-based active pharmaceutical ingredients (api) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plant-based active pharmaceutical ingredients (api) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the plant-based active pharmaceutical ingredients market by increasing the cost of imported botanical raw materials, extraction solvents, and processing equipment used in plant API production. These impacts have been most pronounced in alkaloid and cannabinoid API segments, particularly in north america and europe where sourcing depends on international plant supply chains. Asia-pacific producers have faced export pricing pressures due to trade barriers. However, tariffs have encouraged domestic cultivation of medicinal plants and localized extraction facilities, supporting supply security and sustainable manufacturing growth.

The plant-based active pharmaceutical ingredients (api) market research report is one of a series of new reports that provides plant-based active pharmaceutical ingredients (api) market statistics, including plant-based active pharmaceutical ingredients (api) industry global market size, regional shares, competitors with a plant-based active pharmaceutical ingredients (api) market share, detailed plant-based active pharmaceutical ingredients (api) market segments, market trends and opportunities, and any further data you may need to thrive in the plant-based active pharmaceutical ingredients (api) industry. This plant-based active pharmaceutical ingredients (api) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plant-based active pharmaceutical ingredients (APIs) are biologically active compounds obtained from plants that are used in the development of medications. These ingredients play a vital role due to their therapeutic properties, which may involve treating, preventing, or managing different health conditions.

The primary categories of plant-based active pharmaceutical ingredients (APIs) include alkaloids, glycosides, cannabinoids, flavonoids, terpenes and terpenoids, polyphenols, saponins, and additional types. Alkaloids form a varied class of naturally occurring organic substances that typically feature basic nitrogen atoms. Plant-derived APIs come from diverse origins, such as leaves, roots, bark, flowers, seeds, fruits, resins, gums, and various other natural materials. These compounds reach consumers via several distribution methods, including online stores, supermarkets and hypermarkets, specialty health shops, and foodservice outlets, serving a range of sectors like pharmaceuticals, nutraceuticals, herbal products, and more.

The plant-based active pharmaceutical ingredients (API) market consists of sales of botanical extracts, plant-based steroids, essential oils, flavonoids, and botanical extracts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.